Pfaffinger · Frontiers in neuroscience 2025 · narrative review · n=?

Gut dysbiosis as a potential driver of Parkinson's and Alzheimer's disease pathogenesis.

Cited 23 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review summarizing mechanistic and observational literature without systematic search or original data

PubMed 40880851 · doi:10.3389/fnins.2025.1600148 · record verified 2026-08-27

What was done

This narrative review integrates current published literature investigating how gut microbial dysbiosis may influence the pathogenesis of Alzheimer's disease (AD) and Parkinson's disease (PD). The authors summarize pathological mechanisms, examine differences in fecal bacterial taxa between AD/PD patients and healthy controls (specifically short-chain fatty acid [SCFA]-producing and lipopolysaccharide [LPS]-expressing bacteria), and detail hypothesized pathways connecting microbial metabolites to neuroinflammation, blood-brain barrier permeability, and neural propagation.

What was found

The abstract reports no quantitative figures, effect estimates, or sample sizes. Qualitatively, it reports that AD and PD patients exhibit altered fecal microbiota compared to controls, characterized by reductions in SCFA-producing bacteria and increases in LPS-expressing bacteria, which are hypothesized to promote systemic inflammation, protein misfolding, and disease progression.

Why it matters

It organizes current hypotheses on how the microbiome-gut-brain axis could influence neurodegeneration, highlighting potential avenues for biomarker development or personalized microbiome-targeted therapeutics.

Limits

As a narrative review, it synthesizes existing literature without systematic search criteria, quality appraisal, or meta-analytic pooling, and presents no new empirical data. The abstract provides no quantitative metrics, and causality between observed gut dysbiosis and neurodegenerative onset remains unestablished.

Cited by